ECS Botanics (ASX:ECS) is well advanced with the upcoming launch of VESIsorb Cannabis soft gel capsules.
To strengthen its B2C business ahead of the launch ECS has established a Medical Advisory Board (MAB) to provide expert guidance, oversight, and education to the medical industry to support patient outcomes.
All MAB members are experienced medical practitioners, widely regarded as thought leaders in medicinal cannabis medicine. They understand the importance of good clinical practice, sound advice, and the value of medicinal cannabis as an option to support patient wellbeing.
"We are excited to announce the formation of our Medical Advisory Board. Their expertise will be crucial as we continue rolling out our B2C offerings, ensuring patients achieve the best outcomes with our medicinal cannabis products,” Managing Director, Nan-Maree Schoerie, said.
"Each advisor brings a profound understanding of medicinal cannabis and its impact on patient well-being. The MAB will play a pivotal role in the success of our entire ECS product line, including the new Avani Advanced Cannabis Soft Gel Capsules. Powered by VESIsorb, these capsules offer four times the absorption rate and act three times faster compared to current market options.
"I look forward to this phase of growth, supported by a team of medicinal cannabis experts as we expand our range of high-quality, Australian-grown medicinal cannabis products to reach more patients worldwide.”
ECS will launch its first product utilising the advanced delivery system, VESIsorb this month. VESIsorb is a patented system that is clinically proven to deliver quicker onset, better absorption, and higher efficiency in cannabis-based products. will be the first product line, Terphogz, mid-market range, Avani and budget line, OzSun.
ECS holds a ten-year exclusive license agreement for VESIsorb from global cannabis company, Geocann, covering Australia, New Zealand, the United Kingdom, and extends to Europe for ECS product formulations.